XenoPort, Inc. (XNPT)

EclecticRecluse (74.40) Submitted: 11/17/2009 4:54:47 AM : Start Price: $15.96 XNPT Score: -4.38

Negative Earnings Surprise

AndrewGreenBull (97.68) Submitted: 11/16/2009 10:26:23 AM : Start Price: $17.47 XNPT Score: -5.95

2/09/2010

Alex1963 (97.61) Submitted: 9/17/2009 1:18:45 PM : Start Price: $24.50 XNPT Score: -36.06

from article in Morn* 9/17/09
announced positive results Thursday from a Phase IIb clinical trial for XP13512 for neuropathic pain associated with post-herpetic neuralgia. The drug candidate was successful in demonstrating statistically significant results over placebo at all dosing levels, and we plan to slightly raise our fair value estimate in the wake of this news. The 14-week, double-blind trial evaluated the safety and efficacy of XP13512 and had a total enrollment of 375 subjects with PHN who experienced pain following the healing of the herpes zoster (shingles) skin rash for at least three months. XP13512 was statistically significan t on the primary endpoint of the trial, which was improvement from baseline in the 24-hour average pain intensity score. We think this is great news for XenoPort, which experienced a setback with XP13512 in April, when the drug failed a Phase II study for pain associated with diabetes. XenoPort has partnered with GlaxoSmithKline GSK on the drug, which is still on track for final approval from the Food and Drug Administration for restless leg syndrome, having met all primary goals in its Phase III trials.

streetguru (45.94) Submitted: 1/25/2009 11:03:18 AM : Start Price: $24.24 XNPT Score: -65.52

This is a winner. FDA had some formating issues with Solzira data. Eventually this drug will pass. Target 55

TMFBiologyFool (91.01) Submitted: 11/10/2008 11:00:30 AM : Start Price: $34.50 XNPT Score: -72.64

Purely a value play. Doesn't deserve a 13% drop because Solzira's NDA has to be reformatted.

mukwonago53149 (75.55) Submitted: 1/16/2008 9:24:14 PM : Start Price: $61.40 XNPT Score: +56.13

http://www.fool.com/investing/small-cap/2008/01/16/stocks-on-bubble-watch.aspx

JakeTomato (34.37) Submitted: 1/11/2008 12:41:37 PM : Start Price: $60.83 XNPT Score: -54.15

Valuable potential medical technology for a variety of common clinical problems.

morningstarboy (< 20) Submitted: 12/5/2007 1:03:04 PM : Start Price: $54.49 XNPT Score: +47.16

As of close of business on 12/04/2007, this was a 1-star Morningstar stock that was trading at more than double it's Morningstar fair value.

WiseWallstWhiz (< 20) Submitted: 8/20/2007 4:21:36 PM : Start Price: $39.57 XNPT Score: -38.18

Xenoport's drug delivery technology shows great promise given its pairing with GSK's restless leg syndrome drug and their recent partnership agreement expected to bring in cashflows north of $600M upon hitting milestones....Right now in Phase III clinical trials...Most importantly this companies drug delivery technology can be paired with various drugs on the market giving it ultimately a great platform to build a solid business upon....

indexmagnet (< 20) Submitted: 5/14/2007 5:59:04 PM : Start Price: $40.79 XNPT Score: -36.53

Rare non binary biotech. Pro-drug transporter works, pipeline good -RLS/GERD/Migraine/Parkinsons. May get taken out by big pharma or become big pharma. Each way bet.

majakblue (< 20) Submitted: 4/25/2007 11:34:26 PM : Start Price: $40.20 XNPT Score: -36.56

They have a product in phase III trials. Stock will keep going up until product goes kapluuie or executives start buying castles. Pull out of this one if there is a negative report on the product!

docmase (< 20) Submitted: 2/6/2007 2:01:21 PM : Start Price: $24.75 XNPT Score: -13.80

This company has a strong product candidate in XP512 for the treatment of restless legs syndrome that is different in mechanism of action from all the other RLS treatments on the market.